Cita APA (7a ed.)
Ngoc, H. B., Do, K. H., Linh, D. M., & Nguyen, V. T. (2026 Supplement 19). Treatment outcomes with first-line EGFR tyrosine kinase inhibitors in Vietnamese metastatic NSCLC patients harboring compound EGFR mutations. Journal of Clinical Oncology, 44, 288-315.
Cita Chicago Style (17a ed.)
Ngoc, Hoang Bao, Kien Hung Do, Do Mai Linh, y Van Tai Nguyen. "Treatment Outcomes with First-line EGFR Tyrosine Kinase Inhibitors in Vietnamese Metastatic NSCLC Patients Harboring Compound EGFR Mutations." Journal of Clinical Oncology 44 (2026 Supplement 19): 288-315.
Cita MLA (9a ed.)
Ngoc, Hoang Bao, et al. "Treatment Outcomes with First-line EGFR Tyrosine Kinase Inhibitors in Vietnamese Metastatic NSCLC Patients Harboring Compound EGFR Mutations." Journal of Clinical Oncology, vol. 44, 2026 Supplement 19, pp. 288-315.
Precaución: Estas citas no son 100% exactas.